Galactosemia

Galactosemia is a rare inherited metabolic disorder that affects the body's ability to process galactose, a sugar found in milk. With early diagnosis and strict dietary management, individuals with galactosemia can lead relatively healthy lives, although some may still experience developmental or long-term complications.

  • Cause: Caused by mutations in genes that produce enzymes (e.g., GALT) needed to break down galactose. The most common form is classic galactosemia, caused by a deficiency in the enzyme galactose-1-phosphate uridyltransferase (GALT).

  • Features: Symptoms can appear shortly after birth and include vomiting, diarrhea, jaundice, liver enlargement, cataracts, and failure to thrive. If untreated, it can lead to intellectual disability, speech and motor problems, and ovarian failure in females.

  • Diagnosis: Diagnosed through newborn screening tests and confirmed with enzyme activity or genetic testing.

  • Treatment: The primary treatment is a lifelong strict avoidance of galactose, primarily by excluding milk and dairy products from the diet.

Active Trials

  • TITLE:

    SPONSOR:

    INDICATION:

    PROTOCOL:

    PHASE:

    DESCRIPTION:

    STATUS:

    RECRUITING PATIENTS:

    RDR LOCATION:

    Inquire About Trial →

Past Trials

  • TITLE: Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia

    SPONSOR: Applied Therapeutics, Inc.

    INDICATION: Classic Galactosemia

    PROTOCOL: AT-007-1002

    PHASE: 1-3

    DESCRIPTION: This study is designed to assess the clinical benefit as well as the safety, pharmacokinetics (PK), and pharmacodynamics (PD) (reduction of galactitol levels) of AT-007 in pediatric subjects with Classic Galactosemia (CG).

    This Study is a randomized, double-blind, placebo-controlled study in pediatric subjects with CG. Children with CG ages 2 through 17 years will be enrolled. The study is designed to assess the clinical benefit using validated, standardized Clinical Outcome Assessments (COAs) as well as the safety, PK, and PD (reduction of galactitol levels) of AT-007 in pediatric subjects with CG. The study consists of 2 main parts, Part A and Part B, and an open-label extension (OLE).

    STATUS: Active

    RECRUITING PATIENTS: No

    RDR LOCATION: Georgia